“It hasn’t become the gold standard yet. There are still a lot of inter-reader reliability issues. The same MRI scans, read by different radiologists, may be read differently," says one urologist.
"It certainly looks like these new therapies will provide better results. From the research and literature, it looks like significant improvement," says one urologist.
For this installment of “Speak Out,” urologists were asked to discuss recent studies indicating African-American men with prostate cancer may be put on active surveillance without suffering complications and that they respond to radiation and some chemotherapy better than Caucasian men.
“It’s actually an exciting time for patients who have metastatic urothelial cancers and prostate cancers or advanced prostate cancers because there are a lot more products on the way, like the newer hormone agents for prostate cancer and the new immunologic agents like PARP inhibitors for different types of cancers," says one urologist.
Leonard G. Gomella, MD, Tanya Dorff, MD, Scott Eggener, MD, and Jorge Garcia, MD, all reflect on prostate cancer treatment in 2019.
"Becoming a member of the larger group has given us more bargaining power in the health care marketplace, so we’ve been able to get better health care, not only for us but for our staff," says one urologist.
"In an ideal world, it could work pretty well. We live in a capitalistic society, however, and insurance companies are not going to voluntarily implode in order to make it easy to implement a Medicare for All system," says one urologist.
"I basically choose the procedure based on the patient’s anatomy," says one urologist.
"One is the delay in delivering care. If I order surgery that requires prior authorization, it won’t always come through in a timely manner, and that impacts patients’ quality of life," says one urologist.
"We start by having a discussion with patients and letting them know about available resources, but that they have to accept some responsibility themselves," says one urologist.